Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

Detalhes bibliográficos
Autor(a) principal: Ergür,Figen Öztürk
Data de Publicação: 2022
Outros Autores: Yıldız,Murat, Şener,Melahat Uzel, Kavurgacı,Suna, Ozturk,Ayperi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372
Resumo: ABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.
id APM-1_3f65e0ad81c550fd5421d493093f4d94
oai_identifier_str oai:scielo:S1516-31802022000300372
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective studyFavipiravir [supplementary concept]COVID-19PneumoniaCoronavirus disease 2019Adverse effectAviganABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.Associação Paulista de Medicina - APM2022-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372Sao Paulo Medical Journal v.140 n.3 2022reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2021.0489.r1.13082021info:eu-repo/semantics/openAccessErgür,Figen ÖztürkYıldız,MuratŞener,Melahat UzelKavurgacı,SunaOzturk,Ayperieng2022-05-12T00:00:00Zoai:scielo:S1516-31802022000300372Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2022-05-12T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
title Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
spellingShingle Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
Ergür,Figen Öztürk
Favipiravir [supplementary concept]
COVID-19
Pneumonia
Coronavirus disease 2019
Adverse effect
Avigan
title_short Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
title_full Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
title_fullStr Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
title_full_unstemmed Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
title_sort Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
author Ergür,Figen Öztürk
author_facet Ergür,Figen Öztürk
Yıldız,Murat
Şener,Melahat Uzel
Kavurgacı,Suna
Ozturk,Ayperi
author_role author
author2 Yıldız,Murat
Şener,Melahat Uzel
Kavurgacı,Suna
Ozturk,Ayperi
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Ergür,Figen Öztürk
Yıldız,Murat
Şener,Melahat Uzel
Kavurgacı,Suna
Ozturk,Ayperi
dc.subject.por.fl_str_mv Favipiravir [supplementary concept]
COVID-19
Pneumonia
Coronavirus disease 2019
Adverse effect
Avigan
topic Favipiravir [supplementary concept]
COVID-19
Pneumonia
Coronavirus disease 2019
Adverse effect
Avigan
description ABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey. METHODS: 357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups. RESULTS: Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed: diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea. CONCLUSION: In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022000300372
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1516-3180.2021.0489.r1.13082021
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.140 n.3 2022
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209268638154752